Repligen (NASDAQ:RGEN) was upgraded by equities researchers at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued on Tuesday.

A number of other equities analysts also recently issued reports on the company. Zacks Investment Research downgraded Repligen from a “buy” rating to a “hold” rating in a research note on Saturday, October 6th. Janney Montgomery Scott restated a “buy” rating on shares of Repligen in a research note on Thursday, October 4th. HC Wainwright assumed coverage on Repligen in a research note on Wednesday, September 26th. They issued a “neutral” rating and a $49.00 price target on the stock. JPMorgan Chase & Co. lifted their target price on Repligen to $60.00 and gave the company an “overweight” rating in a research report on Monday, September 24th. Finally, Citigroup lifted their target price on Repligen from $45.00 to $56.00 and gave the company a “buy” rating in a research report on Friday, July 20th. Four research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $51.86.

RGEN stock opened at $57.48 on Tuesday. The firm has a market capitalization of $2.43 billion, a PE ratio of 83.30, a PEG ratio of 4.46 and a beta of 0.69. Repligen has a 1 year low of $29.56 and a 1 year high of $58.99.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Thursday, August 2nd. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.18 by ($0.02). The firm had revenue of $47.73 million during the quarter, compared to analysts’ expectations of $45.84 million. Repligen had a return on equity of 5.05% and a net margin of 13.49%. The business’s quarterly revenue was up 47.0% on a year-over-year basis. During the same quarter last year, the business earned $0.20 earnings per share. As a group, research analysts predict that Repligen will post 0.71 earnings per share for the current year.

In related news, CFO Jon Snodgres sold 14,460 shares of Repligen stock in a transaction on Tuesday, August 28th. The stock was sold at an average price of $52.79, for a total transaction of $763,343.40. Following the transaction, the chief financial officer now directly owns 20,899 shares in the company, valued at $1,103,258.21. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Anthony Hunt sold 27,566 shares of Repligen stock in a transaction on Monday, September 10th. The shares were sold at an average price of $57.71, for a total value of $1,590,833.86. Following the transaction, the chief executive officer now owns 255,017 shares in the company, valued at $14,717,031.07. The disclosure for this sale can be found here. Insiders have sold 88,884 shares of company stock worth $4,693,683 over the last quarter. 1.40% of the stock is owned by company insiders.

A number of large investors have recently bought and sold shares of RGEN. SG Americas Securities LLC bought a new stake in Repligen during the second quarter valued at about $135,000. Smith Asset Management Group LP raised its holdings in Repligen by 1,511.8% during the second quarter. Smith Asset Management Group LP now owns 4,658 shares of the biotechnology company’s stock valued at $219,000 after acquiring an additional 4,369 shares during the period. Bayesian Capital Management LP bought a new stake in Repligen during the first quarter valued at about $228,000. Benin Management CORP bought a new stake in Repligen during the second quarter valued at about $235,000. Finally, GSA Capital Partners LLP bought a new stake in Repligen during the second quarter valued at about $250,000. 92.50% of the stock is currently owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

See Also: Are Wall Street analysts’ stock ratings worth following?

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.